Advertisement

hautnah

pp 1–5 | Cite as

Therapie der atopischen Dermatitis

Zahlreiche Biologika in der Pipeline
  • Thomas WerfelEmail author
Atopische Dermatitis
  • 8 Downloads

Zusammenfassung

Anti-IL-22-Antikörper, Januskinase-Inhibitoren und H4-Rezeptor-Blocker könnten in Zukunft das Therapiearsenal gegen schwere Neurodermitisformen erweitern.

Schlüsselwörter

Interleukin Januskinase Juckreiz 

Therapy of atopic dermatitis

Numerous biologics being developed

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

T. Werfel gibt an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Literatur

  1. 1.
    Gerbens LAA et al (2018) Methotrexate and azathioprine for severe atopic dermatitis: a 5‑year follow-up study of a randomized controlled trial. Br J Dermatol 178:1288–1296CrossRefGoogle Scholar
  2. 2.
    van der Schaft J et al (2015) Drug survival for ciclosporin A in a long-term daily practice cohort of adult patients with atopic dermatitis. Br J Dermatol 172:1621–1627CrossRefGoogle Scholar
  3. 3.
    Guttman-Yassky E et al (2018) Dupilumab progressively improves systemic and 4. cutaneous abnormalities in atopic dermatitis patients. J Allergy Clin Immunol:k4.  https://doi.org/10.1016/j.jaci.2018.08.022 Google Scholar
  4. 4.
    Werfel T (2018) Novel systemic drugs in treatment of atopic dermatitis: results from phase II and phase III studies published in 201 7/2018. Curr Opin Allergy Clin Immunol 18:432–437CrossRefGoogle Scholar
  5. 5.
    Werfel T et al (2018) New aspects in systemic treatment of atopic dermatitis. Hautarzt 69:217–224CrossRefGoogle Scholar
  6. 6.
    de Bruin-Weller M et al (2018) Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo- controlled, randomized phase III clinical trial (LIBERTY AD CAFE). Br J Dermatol 178:1083– 1101CrossRefGoogle Scholar
  7. 7.
    Blauvelt A et al (2019) Dupilumab does not affect correlates of vaccine-induced immunity: a randomized, placebo- controlled trial in adults with moderate- to-severe atopic dermatitis. J Am Acad Dermatol 80:158–167CrossRefGoogle Scholar
  8. 8.
    Rabe KF et al (2018) Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med 378:2475–2485CrossRefGoogle Scholar
  9. 9.
    Castro M et al (2018) Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med 378:2486–2496CrossRefGoogle Scholar
  10. 10.
    Wollenberg A et al (2018) Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment. J Allergy Clin Immunol Pract 6:1778–1780CrossRefGoogle Scholar
  11. 11.
    Treister AD et al (2018) Risk factors for dupilumab-associated conjunctivitis in patients with atopic dermatitis. JAMA Dermatol 154:1208–1211CrossRefGoogle Scholar
  12. 12.
    Ruzicka T et al (2017) Anti-Interleukin-31 receptor a antibody for atopic dermatitis. N Engl J Med 376:826–835CrossRefGoogle Scholar
  13. 13.
    Kabashima K et al (2018) Nemolizumab in patients with moderate-to-severe atopic dermatitis: randomized, phase II, long-term extension study. J Allergy Clin Immunol 142(4):121–130CrossRefGoogle Scholar
  14. 14.
    Wollenberg A et al (2019) Treatment of atopic dermatitis with tralokinumab, an anti-IL - 13 mAb. J Allergy Clin Immunol 143:135–141CrossRefGoogle Scholar
  15. 15.
    Simpson EL et al (2018) Efficacy and safety of lebrikizumab (an anti-IL - 13 monoclonal antibody) in adults with moderate-to- severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol 78:863–871CrossRefGoogle Scholar
  16. 16.
    Guttman-Yassky E et al (2018) Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial. J Am Acad Dermatol 78:872–881CrossRefGoogle Scholar
  17. 17.
    Brunner PM et al (2019) Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab. J Allergy Clin Immunol 143:142–154CrossRefGoogle Scholar
  18. 18.
    Guttman-Yassky E et al (2018) IL - 17C: a unique epithelial C ytokine with potential for  targeting across the spectrum of atopic dermatitis and psoriasis. J Invest Dermatol 138:1467–1469CrossRefGoogle Scholar
  19. 19.
    Schaper-Gerhardt K et al (2018) Histamine H 4 receptor and skin disorders. Br J PharmacolGoogle Scholar
  20. 20.
    Werfel TLV, Asher A et al (2018) Efficacy and safety of the histamine H4 receptor antagonist ZPL-3893787 in atopic dermatitis. J Allergy Clin Immunol.  https://doi.org/10.1016/j.jaci.2018.07.047 Google Scholar
  21. 21.
    Guttman-Yassky E et al (2019) Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J Am Acad Dermatol 80(4):913–921.e9CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Klinik für Dermatologie, Allergologie und VenerologieMedizinische Hochschule HannoverHannoverDeutschland

Personalised recommendations